Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2013-06-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.2013.789016PMID 23581572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.

  2013cited by this paper
• Why do I treat HBeAg‐negative chronic hepatitis B patients with pegylated interferon?

  2013cited by this paper
• A pilot randomized controlled trial of dual‐plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy

  2012cited by this paper
• Hepatitis B viral load and risk of HBV-related liver disease: from East to West?

  2012influential reference
• Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

  2012cited by this paper
• Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?

  2012cited by this paper
• Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.

  2012cited by this paper
• Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.

  2011cited by this paper
• Treatment of chronic hepatitis B virus infection in resource‐constrained settings: expert panel consensus

  2011cited by this paper
• Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration

  2011cited by this paper
• Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity

  2011cited by this paper
• Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

  2011cited by this paper
• Milestones and perspectives in viral hepatitis B

  2011cited by this paper
• Restored Circulating Invariant NKT Cells Are Associated with Viral Control in Patients with Chronic Hepatitis B

  2011cited by this paper
• Immunosuppressive functions of hepatic myeloid‐derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus

  2011cited by this paper
• Safety and immunogenicity of hepatitis B surface antigen‐pulsed dendritic cells in patients with chronic hepatitis B

  2011cited by this paper
• Recent advances in the treatment of chronic hepatitis B

  2011cited by this paper
• Effect of an immunogenic complex containing WHV viral particles and non‐neutralizing anti‐HBs antibodies on the outcome of WHV infection in woodchucks

  2011cited by this paper
• Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV.

  2011cited by this paper
• Management of Chronic Hepatitis B: Status and Challenges beyond Treatment Guidelines

  2010cited by this paper
• Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine.

  2010cited by this paper
• Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.

  2010cited by this paper
• Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers.

  2010cited by this paper
• [Management of chronic hepatitis B].

  2010cited by this paper
• Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection

  2010cited by this paper
• Pathogenesis of hepatitis B virus infection.

  2010cited by this paper
• The molecular basis of the failed immune response in chronic HBV: therapeutic implications.

  2010cited by this paper
• Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference

  2009cited by this paper
• Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus

  2009cited by this paper
• Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment

  2009cited by this paper
• α-Galactosylceramide in Chronic Hepatitis B Infection: Results from a Randomized Placebo-Controlled Phase I/ II Trial

  2009cited by this paper
• Liver Sinusoidal Endothelial Cell Lectin, LSECtin, Negatively Regulates Hepatic T-Cell Immune Response

  2009cited by this paper
• Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries

  2009cited by this paper
• Randomized Controlled Study Investigating Viral Suppression and Serological Response following Pre-S1/Pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B

  2009cited by this paper
• Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.

  2008cited by this paper
• A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients

  2008cited by this paper
• DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.

  2008cited by this paper
• Management of chronic hepatitis B.

  2008cited by this paper
• T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes.

  2008cited by this paper
• Pathogenesis of hepatitis B virus infection.

  2007cited by this paper
• Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.

  2007cited by this paper
• The immunology of hepatitis B.

  2007cited by this paper
• Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection

  2007cited by this paper
• Combination of an Antiviral Drug and Immunomodulation against Hepadnaviral Infection in the Woodchuck Model

  2007cited by this paper
• Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.

  2006cited by this paper
• Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load

  2006cited by this paper
• The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

  2006cited by this paper
• Immunobiology and pathogenesis of viral hepatitis.

  2006cited by this paper
• Therapeutic vaccination in chronic hepatitis B virus carriers

  2006cited by this paper
• In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.

  2005cited by this paper
• Immunomodulatory therapy for chronic hepatitis B virus infection

  2005cited by this paper
• Toll-Like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo

  2005cited by this paper
• Therapeutic vaccination against chronic hepatitis B virus infection.

  2005cited by this paper
• Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study.

  2005cited by this paper
• The efficacy and safety of thymosin alpha‐1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial

  2005cited by this paper
• Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy

  2004cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004cited by this paper
• Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B.

  2004cited by this paper
• Induction of oral immune regulation towards liver‐extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial

  2004cited by this paper
• Efficacy of hepatitis B vaccination and interferon‐α‐2b combination therapy versus interferon‐α‐2b monotherapy in children with chronic hepatitis B

  2004cited by this paper
• Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

  2003cited by this paper
• Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection

  2003cited by this paper
• Propagermanium: a nonspecific immune modulator for chronic hepatitis B

  2003cited by this paper
• Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers.

  2002cited by this paper
• Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin‐2 in patients with chronic hepatitis B

  2002cited by this paper
• Activated Intrahepatic Antigen-Presenting Cells Inhibit Hepatitis B Virus Replication in the Liver of Transgenic Mice1

  2002cited by this paper
• Therapeutic vaccination in chronic hepatitis B

  2002cited by this paper
• Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications.

  2001cited by this paper
• Efficacy and limitations of a specific immunotherapy in chronic hepatitis B.

  2001cited by this paper
• Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.

  2001cited by this paper
• The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection

  2000cited by this paper
• A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.

  2000cited by this paper
• Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens.

  1999cited by this paper
• Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells.

  1999cited by this paper
• A pilot study of the CY‐1899 T‐cell vaccine in subjects chronically infected with hepatitis B virus

  1999cited by this paper
• Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

  1999cited by this paper
• Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans.

  1999cited by this paper
• What once was lost, now is found: Restoration of hepatitis B–specific immunity after treatment of chronic hepatitis B

  1999cited by this paper
• Recombinant Duck Interferon Gamma Inhibits Duck Hepatitis B Virus Replication in Primary Hepatocytes

  1999cited by this paper
• Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection.

  1999cited by this paper
• HBV‐specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro‐ and anti‐inflammatory cytokines

  1999cited by this paper
• Double‐blind, randomized controlled trial of interleukin‐2 treatment of chronic hepatitis B

  1998cited by this paper
• Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B.

  1997cited by this paper
• Predominant T‐helper 1 cytokine profile of hepatitis B virus nucleocapsid‐specific T cells in acute self‐limited hepatitis B

  1997cited by this paper
• Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice.

  1997cited by this paper
• Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy

  1995cited by this paper
• Hepatitis B virus immunopathogenesis.

  1995cited by this paper
• Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy.

  1995cited by this paper
• Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B.

  1995cited by this paper
• A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group.

  1994cited by this paper
• Changes in cytokine production during therapy with Granulocyte‐macrophage colony‐stimulating factor in patients with chronic hepatitis B

  1994cited by this paper
• Specific vaccine therapy in chronic hepatitis B infection.

  1994cited by this paper
• Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.

  1993cited by this paper
• Levamisole and interferon in children with chronic hepatitis B

  1993cited by this paper
• Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitis

  1993cited by this paper

• Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B

  2022cites this paper
• Current trends in hepatitis B vaccination

  2016cites this paper
• Hepatitis B virus-related liver diseases: Identity and evidence-based control strategy

  2016cites this paper
• Vaccine therapy update for pregnant, immunocompromised, and chronic diseases patients.

  2015cites this paper